News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Top 7 Jaw-Dropping Pipeline Blowups This Year 12/5/2016
NeuroDerm (NDRM) to Discontinue ND0612H Phase III, Suspend iNDiGO After FDA Meeting 12/5/2016
CSL Behring Presents New Phase III Analysis Of IDELVION For Hemophilia B At The 2016 American Society of Hematology Annual Meeting 12/5/2016
AOP Orphan Pharmaceuticals AG And PharmaEssentia Announce Pivotal Phase III Results For Ropeginterferon Alfa-2b In Polycythemia Vera At The American Society of Hematology Annual Meeting 2016 12/5/2016
AbbVie (ABBV) Release: IMBRUVICA (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis And Long-Term RESONATE-2 Follow-Up Data At American Society of Hematology 2016 Show Lasting Efficacy 12/5/2016
Shire (SHPG) Release: Topline Results Of Phase 3 Investigational Study Of VONVENDI [Von Willebrand Factor (Recombinant)] Meets Primary Endpoint Effectively Controlling Bleeding And Blood Loss During Surgical Procedures 12/2/2016
Amgen (AMGN) And Allergan (AGN) Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab 12/2/2016
Pfizer (PFE) Release: LYRICA (pregabalin) Phase III Trial In Pediatric Epilepsy Meets Primary Endpoint 12/1/2016
Amgen (AMGN) And Cytokinetics (CYTK) Release: The Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function In Patients With Chronic Heart Failure 12/1/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia 12/1/2016
GW Pharma (GWPH) Announces Epidiolex (Cannabidiol) Data Presentations And Educational Programs At The American Society Of Epilepsy Annual Meeting 12/1/2016
Bay Area's Aradigm (ARDM) Stock Plunges After Posting Mixed-Data of Two Phase III Antibiotic Studies 12/1/2016
Cytokinetics (CYTK) Announces Start Of GALACTIC-HF, A Phase III Clinical Trial Of Omecamtiv Mecarbil 12/1/2016
Global Blood Therapeutics (GBT) Announces GBT440 Granted Orphan Drug Designation In Europe For Treatment Of Sickle Cell Disease 12/1/2016
Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements In Erectile Function And Mood In Hypogonadal Men Treated With Natesto Nasal Testosterone Gel 11/30/2016
Nymox (NYMX) Reports Additional Positive Results From Completed Fexapotide BPH Phase III Studies Showing Significant Early Response And First-Line Efficacy 11/30/2016
Omeros (OMER) Release: International Consortium Of Complement Experts Receives €1.3 Million Grant To Study Role Of MASP-2 And Lectin Pathway In Traumatic Brain Injury 11/30/2016
Devastation Hits as Eli Lilly (LLY)'s Alzheimer's Drug Flunks Late-Stage Study, Shares Tank 11/29/2016
CytRx (CYTR) Reports Statistically Significant Updated Results From Pivotal Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcomas 11/29/2016
Momenta (MNTA) Announces Positive Top-Line Phase III Results For M923, A Proposed HUMIRA (Adalimumab) Biosimilar 11/29/2016
Nymox (NYMX) Reports Additional Positive Results From Completed Fexapotide BPH Phase III Studies Showing Significant Early Response And First-Line Efficacy 11/29/2016
Astex Pharma (ASTX) To Showcase Its Next-Generation Hypomethylating Agents Being Developed For Treatment Of AML/MDS At The 2016 Annual Meeting Of American Society of Hematology 11/29/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy 11/29/2016
Vtesse Receives Rare Pediatric Disease Designation By The FDA For VTS-270 For The Treatment Of Niemann-Pick Type C1 Disease 11/29/2016
Santen Pharma Announces Phase III SAKURA Program Topline Results In Patients With Non-Infectious Uveitis Of The Posterior Segment 11/28/2016
Recro Pharma (REPH) Reports Positive Top-Line Results From Pivotal Phase III Clinical Trial Of IV Meloxicam 11/28/2016
Eli Lilly (LLY) Alzheimer’s Drug Fails To Show Benefits In Final Stage Clinical Trial 11/28/2016
Foamix Pharma (FOMX) Announces Completion Of Patient Enrollment In Phase 3 Acne Trials For Minocycline Foam FMX101 11/28/2016
Cognition Therapeutics Sees Eli Lilly (LLY) Solanezumab Clinical Trial Results As Support For Its Unique Mechanism For Treatment Of Alzheimer's Disease 11/28/2016
Aimmune (AIMT) Completes Global Enrollment Of Phase III PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy 11/28/2016
Intec Pharma Enters Into Agreement With The Michael J. Fox Foundation Around Its Phase III Trial Recruitment 11/28/2016
The Franchise That Could Bring in Another $20 Billion for Celgene (CELG) 11/23/2016
5 Drug Giants That Could Dominate the $13 Billion Alzheimer's Market 11/23/2016
Galapagos (GLPG.BR) Release: Phase 3 Study With Filgotinib Initiated In Crohn's Disease 11/23/2016
Neurotrope Issues Statement On Eli Lilly (LLY)'s Solanezumab 11/23/2016
ADImmune Corporation Begins Shipments To EU And Phase III Trial In Europe 11/23/2016
AstraZeneca PLC (AZN) Catches a Break as the FDA Lifts Hold on Head And Neck Cancer Trials 11/22/2016
Arog Pharmaceuticals Receives Orphan Drug Designation In The European Union For Crenolanib For The Treatment Of Acute Myeloid Leukemia And Soft Tissue Sarcoma 11/22/2016
DelMar Pharma Delivers An Address And Presents An Overview Of Upcoming GBM Trials With VAL-083 At The CNS Anticancer Drug Discovery Development Conference And Society For NeuroOncology Annual Meeting 11/21/2016
Collegium (COLL) Release: Independent Review Of Xtampza ER Published In Peer-Reviewed Medical Journal 11/21/2016
Keryx (KERX) Announces Case Study Data Of Auryxia Presented At American Society of Nephrology’s Kidney Week 11/21/2016
Onxeo Announces 9th Positive DSMB Recommendation To Continue Livatag Relive Phase III Trial In HCC 11/21/2016
Omeros (OMER) Announces Successful Outcome Of OMIDRIA Pediatric Cataract Trial 11/21/2016
CEL-SCI (CVM) Submits Response To FDA In Connection With Partial Clinical Hold On Phase III Clinical Trial 11/21/2016
Gilead (GILD) Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency 11/18/2016
As Eli Lilly (LLY)'s ALZ Data Looms, Here Are Some Things Investors Need to Know 11/18/2016
Long-Term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results And Demonstrates Superior Two- And Four-Year Survival Rates 11/18/2016
Investors Hold Their Breath for the "Most Important Event in Biotech"—Here are 5 Stocks to Watch 11/18/2016
Tenax Therapeutics (TENX) Announces Completion Of Enrollment For Phase III LEVO-CTS Trial In Cardiac Surgery 11/18/2016
Janssen Pharmaceutical Companies Release: Phase 3 Study Results Supporting U.S. FDA And European Commission (EC) Approvals Of STELARA In The Treatment Of Moderately To Severely Active Crohn's Disease Published In The New England Journal of Medicine 11/17/2016
TetraPhase (TTPH) Publishes Phase III IGNITE1 Eravacycline Data In JAMA Surgery 11/17/2016
Sage Bionetworks Release: First-Ever Crowdsourced Prostate Cancer Data-Mining Competition Discovery Impacts And Predicts Patient Survival 11/17/2016
Amgen (AMGN) and Novartis AG (NVS) Keep Lead in Migraine Drug Race on Positive Phase III Data 11/17/2016
NovoCure Presents Interim STELLAR Results At IASLC Suggesting Treatment With Tumor Treating Fields Plus Chemotherapy May Extend Survival Of Patients With Mesothelioma 11/17/2016
PHARNEXT Announces That The Data Safety Monitoring Boardrecommends Continuing The Ongoing Phase 3 Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 11/17/2016
PALOMA-2 Phase 3 Study Published In The New England Journal of Medicine Demonstrates Clinical Benefit Of Pfizer (PFE)’s IBRANCE(palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer 11/17/2016
Gilead (GILD) Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib For Patients With Myelofibrosis 11/17/2016
No Early Success for Regeneron (REGN) and Sanofi (SNY)'s Cholesterol Drug Praluent 11/17/2016
FDA Grants Fast Track Designation For Development Of E2609, Eisai Inc. (ESALF.PK)'s BACE Inhibitor For Early Alzheimer's Disease 11/17/2016
Arog Pharmaceuticals Receives FDA Fast Track Designation For Crenolanib For Advanced Gastrointestinal Stromal Tumors With A D842V Mutation In The PDGFRA Gene 11/17/2016
Grunenthal Has Acquired US-Based Thar Pharma To Expand Its Development Portfolio Of Treatment Options For CRPS (Complex Regional Pain Syndrome), A Serious, Disabling Orphan Disease 11/17/2016
Regeneron (REGN) And Sanofi (SNY) Present Results From Phase 3 MONARCH Study Of Investigational Sarilumab At American College of Rheumatology Annual Meeting 11/16/2016
Boehringer Ingelheim Release: Updated Phase III Results Reinforce Safety And Efficacy Of Praxbind (Idarucizumab) In Urgent Situations 11/16/2016
Janssen R&D Release: New Phase 3 Monotherapy Study Of Sirukumab Versus Humira And Sirukumab Data In An Anti-TNF Refractory Population Reported In The Treatment Of Moderately To Severely Active Rheumatoid Arthritis 11/16/2016
GlaxoSmithKline (GSK)'s Benlysta (Belimumab) Shows Sustained Benefits In Patients With SLE 11/16/2016
Amgen (AMGN)'s Repatha Unclogs Blocked Arteries in Key Study 11/16/2016
Aclaris (ACRS) Announces Positive Top-Line Phase III Results For A-101 In Treating Seborrheic Keratosis, A Common Undertreated Skin Condition 11/16/2016
Boehringer Ingelheim Release: Updated Phase III Results Reinforce Safety And Efficacy Of Praxbind (idarucizumab) In Urgent Situations 11/16/2016
AbbVie (ABBV)'s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease 11/15/2016
Portola (PTLA) Announces Three Phase III APEX Substudy Results Showing Further Benefits Of Treating Acute Medically Ill Patients With Extended-Duration Betrixaban 11/15/2016
Enanta Pharmaceuticals, Inc. Announces Abbvie’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease 11/15/2016
Pfizer (PFE) Announces Results From Phase III OPAL Clinical Development Program Investigating XELJANZ (Tofacitinib Citrate) For Psoriatic Arthritis 11/15/2016
Bayer (BAY) Announces Phase III Study To Evaluate New Pediatric Formulation Of Nifurtimox For Potential Treatment Of Chagas Disease 11/15/2016
CoLucid Pharma (CLCD) Provides SPARTAN Enrollment Update 11/14/2016
FDA Calls It! Seattle Genetics (SGEN)' Adcetris is a Breakthrough for Lymphoma 11/14/2016
Going Up Against AbbVie (ABBV)'s Humira, Johnson & Johnson (JNJ) Presents Less-Than-Stellar Phase III Data 11/14/2016
Sanofi Genzyme (SNY) Says 'We're In' to Alnylam (ALNY), Invests $100 Million to Late-Stage RNAi Hemophilia Trial 11/14/2016
Braeburn Pharma And Camurus Announce Positive Top-Line Phase 3 Results For Long-Acting Buprenorphine (CAM2038) For Treatment Of Opioid Addiction 11/14/2016
Janssen R&D Release: New Phase 3 Data Show SIMPONI ARIA (Golimumab) Significantly Improved Signs And Symptoms In Patients With Active Ankylosing Spondylitis 11/14/2016
Amgen (AMGN) Release: Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis 11/14/2016
GlaxoSmithKline (GSK) Announces Positive Results In Fourth Consecutive Pivotal Trial Of Benlysta (Belimumab) In SLE 11/14/2016
Janssen Pharmaceutical Release: Phase 3b Study Shows Significantly Less Bleeding With XARELTO (Rivaroxaban) Compared To Warfarin In People With Non-Valvular Atrial Fibrillation Following Percutaneous Coronary Intervention With Stenting 11/14/2016
Phase III GiACTA Study Shows Genentech (RHHBY)’s Actemra Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis 11/14/2016
Celgene (CELG) Release: Data On Early Onset Of Efficacy For Oral Otezla (Apremilast) In Active Psoriatic Arthritis Presented At American College of Rheumatology 11/14/2016
Ocular Therapeutix (OCUL) Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA 11/14/2016
Ironwood (IRWD) Highlights ZURAMPIC (lesinurad) Phase III Extension Study Data At American College of Rheumatology 2016 Annual Meeting 11/14/2016
Merck & Co. (MRK)’s KEYTRUDA (pembrolizumab) Significantly Improves Overall Survival Compared To Chemotherapy In Previously Treated Patients with Advanced Bladder (Urothelial) Cancer 11/14/2016
Merck & Co. (MRK) Announces Presentation Of New Findings For ZEPATIER (Elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C At The Liver Meeting 11/14/2016
Reata Pharmaceuticals, Inc. Announces Plan for Global Phase II/III Trial in Chronic Kidney Disease Caused by Alport Syndrome 11/14/2016
ARMO BioSciences' Immunotherapy AM0010 Receives Orphan Drug And Fast Track Designations From The U.S. FDA For The Treatment Of Pancreatic Cancer 11/14/2016
Octapharma USA Announces Two Hemophilia A Clinical Trials To Utilize WILATE 11/14/2016
Eli Lilly (LLY) Release: New Analyses Of Phase 3 Trials Show Improvements In Rheumatoid Arthritis Symptoms Following Treatment With Baricitinib Across Diverse Population Of Patients 11/14/2016
Supernus (SUPN) Provides Business Update 11/14/2016
Intercept Pharma (ICPT) Presents New Data At American Association for Study of Liver Diseases Examining The Effects Of Ocaliva (Obeticholic Acid) On Non-Invasive Assessments Of Liver Fibrosis In Patients With PBC 11/11/2016
Alexion (ALXN) Release: New Long-Term Data Presented At American Association for Study of Liver Diseases Show Reduction In Liver Fibrosis And Cirrhosis In A Cohort Of Patients With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma (Sebelipase Alfa) 11/11/2016
Boehringer Ingelheim Release: Patient Enrollment Completed For RE-DUAL PCI Study Assessing Dabigatran In Atrial Fibrillation Patients After PCI With Stenting 11/11/2016
Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie (ABBV)’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C 11/11/2016
AstraZeneca PLC (AZN) Announces Study Results Show SYMBICORT Improves Lung Function In Pediatric Asthma Patients 11/11/2016
Retrophin (RTRX) Reaches Agreement With FDA Under Special Protocol Assessment For Pivotal Trial Evaluating RE-024 In PKAN 11/11/2016
Regeneron (REGN) And Sanofi (SNY) To Present Data From Phase 3 Praluent (Alirocumab) Injection Clinical Trials At AHA Scientific Sessions 2016 11/11/2016
RedHill Biopharma (RDHL) Reports Positive FDA Type B Meeting on RHB-105 For H. pylori Infection Ahead Of Confirmatory Phase III Study 11/10/2016
Intec Pharma To Sponsor Investigator Meeting For Pivotal Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients 11/10/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces First Patients Enrolled In Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) With RGN-259 11/10/2016
Theratechnologies (TH.TO) Announces Results From The Last Pivotal Phase III Trial Of HIV Long Acting Biologic (LAB) Investigational Antiretroviral Ibalizumab 11/10/2016
Investors Ecstatic as Bristol-Myers Squibb (BMY)'s Opdivo Delivers in Late-Stage Stomach Cancer Study 11/10/2016
Genmab A/S (GEN.CO) Announces Phase III Study Of Daratumumab In Combination With Carfilzomib In Multiple Myeloma 11/10/2016
The Small-Cap Biotech That Could Take Down Biogen (BIIB), Celgene (CELG), Eli Lilly (LLY) and Gilead (GILD) in Alzheimer's 11/9/2016
Investors Hold Their Breath for Gilead (GILD)'s Late-Stage Myelofibrosis Data 11/9/2016
Immunocore Presents Positive Monotherapy Data In Uveal Melanoma At The Society For Melanoma Research (SMR) 2016 Congress 11/9/2016
Pierre Fabre And Array BioPharma (ARRY) Release: COLUMBUS Phase 3 Study Results In BRAF-Mutant Melanoma Presented At Society For Melanoma Research Annual Congress 11/9/2016
Seattle Genetics (SGEN) And Takeda (TKPYY) Complete Enrollment Of Phase III ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) In Frontline Mature T-Cell Lymphoma 11/8/2016
Agile Therapeutics, Inc. Reports Third Quarter 2016 Financial Results And Announces Completion Of Subject Visits For Twirla Phase III SECURE Clinical Trial 11/8/2016
Stocks Rocket as Biogen (BIIB), Ionis Pharma (IONS) Halt Study on Positive Phase III 11/7/2016
Gilead (GILD) Drops Another Bombshell, Will Shift R&D Cash Away From Hep C 11/7/2016
Vertex (VRTX)'s Orkambi Met Primary Endpoint in Phase III Study for Kids With CF 11/7/2016
Pfizer (PFE) To Present Additional Research For XELJANZ (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis And Psoriatic Arthritis 11/7/2016
NovoCure Announces 38 Presentations On Tumor Treating Fields At 21st Annual Scientific Meeting Of The Society Of Neuro-Oncology 11/7/2016
Intec Pharma Announces Protocol Amendment To Phase III Study Of Accordion Pill Carbidopa/Levodopa In Advanced Parkinson's Disease Patients 11/7/2016
AbbVie (ABBV) Receives FDA Orphan Drug Designation For Investigational Medicine Veliparib For The Treatment Of Advanced Squamous Non-Small Cell Lung Cancer 11/7/2016
Exelixis (EXEL) Announces Presentation Of Cobimetinib Combination Therapy Data At The Society For Melanoma Research 2016 Congress That Support Genentech’s Planned Phase III Pivotal Trials 11/7/2016
Alnylam (ALNY) Execs Open Up About Patient Deaths in Abandoned Drug Trial 11/4/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
Relypsa (RLYP) Announces Data On The Treatment And Impact Of Hyperkalemia To Be Presented At ASN Kidney Week 2016 11/4/2016
Innocoll (INNL) Slammed on Flunked Phase III Diabetic Foot Infection Trials 11/4/2016
Seattle Genetics (SGEN) Announces American Society of Hematology 2016 Abstracts Highlighting Company's Expanding Global Leadership In The Development Of Innovative Antibody-Drug Conjugates 11/4/2016
Sanofi Genzyme (SNY) Begins Pivotal Phase III Trial Of Neogaa Investigational Second-Generation Therapy For Pompe Disease 11/4/2016
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug 11/3/2016
Why Alkermes (ALKS)’ Depression Drug Candidate Has a Real Shot at Approval Despite Two Poor Trials 11/3/2016
Eli Lilly (LLY) Release: New Data From Pivotal RA-BEACON Study Show Significant Improvement In Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Baricitinib Compared To Placebo 11/3/2016
RedHill Biopharma (RDHL) Provides Update On Ongoing Phase III And Phase II Studies With BEKINDA And Expected Timing Of Top-Line Results 11/3/2016
Genentech (RHHBY) Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society of Hematology 2016 Annual Meeting 11/3/2016
Atox Bio Announces Independent Safety Monitoring Committee Recommendation To Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections 11/3/2016
Aurinia (ISA.TO) Announces Plans For Single Phase III Clinical Trial For Voclosporin In The Treatment Of Lupus Nephritis Following Successful Completion Of End Of Phase II Meeting With FDA 11/3/2016
Acadia (ACAD) Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia 11/3/2016
Gilead (GILD) Looking Even Weaker on the R&D Front as It Racks Up Some More Clinical Failures in Q3 Report 11/2/2016
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it 11/2/2016
10 Drugs That Could be Johnson & Johnson (JNJ)'s New Blockbusters 11/2/2016
Palatin Tech (PTN) Release: Bremelanotide Meets Co-Primary Endpoints In Palatin's Phase 3 Trials For Hypoactive Sexual Desire Disorder 11/2/2016
Neurim Pharmaceuticals Announces Positive Top-Line Results From Pivotal Phase III Trial Of Paediatric Prolonged-Release Melatonin (“Pedprm”) For Sleep Disturbances In Children With Autism Spectrum Disorders (ASD) 11/2/2016
Flexion (FLXN) Reports Primary Endpoint Met In Clinical Trial Evaluating Investigational Drug Candidate Zilretta In Type 2 Diabetes Patients With Knee Osteoarthritis 11/2/2016
Baxter International (BAX) Initiates Clinical Trial For Citrate Anticoagulant For Use During Continuous Renal Replacement Therapy 11/2/2016
AstraZeneca Canada (AZN) Release: Lynparza (Olaparib) Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit For Women With Ovarian Cancer 11/1/2016
Lexicon Pharma (LXRX) Announces Publication Of TELESTAR Study Results For Telotristat Ethyl In The Journal Of Clinical Oncology 11/1/2016
Novartis AG (NVS)' Breast Cancer Contender Gets a Fast Track Ticket to the FDA, Will Take on Pfizer (PFE) 11/1/2016
Can-Fite BioPharma (CFBI) Advances Towards A Pivotal Phase III Clinical Trial In Psoriasis With Piclidenoson (CF101) Following Reaching Agreement With EMA 11/1/2016
Intercept Pharma (ICPT) Announces Ocaliva (Obeticholic Acid) Data In PBC To Be Presented At The 2016 AASLD Annual Meeting 11/1/2016
Now Enrolling: Global Phase 3 Clinical Study To Evaluate Eisai Inc. (ESALF.PK)'s BACE Inhibitor In Early Alzheimer's Disease 10/31/2016
Hemispherx (HEB) Announces Identification Of High Responder Patient Subgroup From Ampligen Phase III Trial In Patients With CFS/ME 10/31/2016
Catalyst Pharma (CPRX) Receives Special Protocol Assessment (SPA) From The FDA For Second Phase III Clinical Trial Evaluating Firdapse For The Treatment Of LEMS 10/31/2016
Ironshore Pharma Presents New Pivotal Trial Data At AACAP Meeting 10/28/2016
Aerie (AERI) Reports Positive Topline Efficacy Results Of Rocket 4 Phase 3 Trial Of Rhopressatm (Netarsudil Ophthalmic Solution) 0.02% 10/28/2016
The EMA Accepts To Assess The Marketing Authorization Application From PharmaMar For Aplidin 10/28/2016
Eisai Inc. (ESALF.PK) Announces Initiation Of Two Phase 3 Clinical Trials With FYCOMPA (Perampanel) 10/28/2016
FDA Slaps Clinical Hold on AstraZeneca PLC (AZN)'s Phase III Head and Neck Cancer Program 10/27/2016
GlaxoSmithKline (GSK) Presents New Data For Shingles Candidate Vaccine At IDWeek Scientific Conference 10/27/2016
Vertex (VRTX) Presents Long-Term Data Demonstrating That ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) Show The Potential To Modify The Progression Of CF 10/27/2016
Alexion (ALXN) Initiates Simultaneous Registration Trials Of ALXN1210 For Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) And Atypical Hemolytic Uremic Syndrome (aHUS) 10/27/2016
Study Stopped Early as Merck & Co. (MRK)'s Immunotherapy Drug Wows in Bladder Cancer Trial 10/27/2016
Immune Pharma Receives FDA Guidance For Low Dose IL-2 In Combination With Phase III Pivotal Trial Of Its AML Therapy Ceplene 10/27/2016
Lannett (LCI) Announces Successful Phase III Clinical Trial Results For Proprietary C-Topical Product 10/27/2016
GlaxoSmithKline (GSK) Terminates Development of Losmapimod for COPD 10/26/2016
Boehringer Ingelheim's Adalimumab Biosimilar Candidate Shows Similar Efficacy And Safety Profile To Humira In Pivotal Phase III Study 10/26/2016
ProMetic Life Sci (PFSCF.PK)'s Plasminogen Meets Primary And Secondary End Points In Pivotal Phase 2/3 Trial 10/26/2016
Dynavax (DVAX) Presents Data Showing That HEPLISAV-B Provides Significantly Higher Seroprotection Rates Against Hepatitis B Infection In Populations Known To Have A Reduced Immune Response To Currently Licensed Vaccines 10/26/2016
AstraZeneca PLC (AZN) Breathes a Sigh of Relief as Lynparza Delays Ovarian Cancer Progression in Phase III Test 10/26/2016
Boehringer Ingelheim’s Adalimumab Biosimilar Candidate Shows Similar Efficacy And Safety Profile To Humira In Pivotal Phase III Study 10/26/2016
AEterna Zentaris (AEZS) Completes Patient Recruitment For Confirmatory Phase III Trial Of Macrilen 10/26/2016
Tiny Dipexium (DPRX) Craters After Lead Drug Locilex Flunks Phase III Trials 10/25/2016
Bay Area's Global Blood Therapeutics (GBT) and the FDA Finally Reach Agreement on Trial Design for Sickle Cell Disease Drug 10/25/2016
DBV Tech Release: Topline Results From Two-Year Follow-Up Study Of Viaskin Peanut Show Long-Lasting And High Levels Of Desensitization To Peanut 10/25/2016
Alkermes (ALKS) Rockets as Depression Drug Aces Key Late-Stage Trial 10/24/2016
Boehringer Ingelheim Release: Efficacy Of Ofev (Nintedanib) Reinforced In Range Of Patients With IPF In New Analyses Presented At CHEST 10/24/2016
How 3 Huge Discoveries in 2016 are Moving Us Closer to a Breast Cancer Cure 10/24/2016
Gilead (GILD) Touts 2-Year Late-Stage Descovy-Truvada HIV Data 10/24/2016
Faron Pharmaceuticals Ltd. Release: First Traumakine Phase III Patient In Japan Recruited For The Treatment Of Acute Respiratory Distress Syndrome And Update On Pan-European Phase III Traumakine Trial 10/24/2016
Alzheon Publishes New Analyses From Phase III Studies Showing Clinical Benefit Of Tramiprosate In Alzheimer’s Patients Who Are Carriers Of APOE4, The Major Genetic Risk Factor In Up To 65 Percent Of Alzheimer’s Patients 10/24/2016
Gilead (GILD) Presents Results From Phase 3 Studies Evaluating Switching To Descovy (FTC/TAF)-Based Regimens From Truvada (FTC/TDF)-Based Regimens 10/24/2016
Inovio Pharma (INO) Shares Crash as the FDA Places Hold on Its Phase III HPV Program 10/24/2016
CytoDyn (CYDY) Files Protocol For Extended Access To PRO 140 For Patients Who Reach The End Of PRO 140 Pivotal Phase III Trial 10/24/2016
CEL-SCI (CVM) Provides Update On Partial Clinical Hold On Phase III Clinical Trial 10/21/2016
Amgen (AMGN)'s Xgeva Meets Primary Endpoints in Late-Stage Study, Secondary Endpoints Missed 10/21/2016
Boston Biomedical Initiates Canstem303c: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Pretreated Advanced Colorectal Cancer 10/21/2016
Rigel (RIGL)'s Bleeding Disorder Drug Flunks Phase III Test, Stock Tanks 10/20/2016
Theravance Biopharma (TBPH) And Mylan (MYL) Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 10/20/2016
Gilead (GILD) Announces SVR12 Rates From Four Phase III Studies Of A Once-Daily, Fixed-Dose Combination Of Sofosbuvir, Velpatasvir And Voxilaprevir In Treatment-Naïve And Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients 10/20/2016
Seattle Genetics (SGEN) Demonstrates Commitment To Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations At ISHL 2016 10/20/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Receives Positive Nice Recommendation For Adults With Chronic Plaque Psoriasis 10/20/2016
Dipexium Pharmaceuticals (DPRX) Provides Update On Availability Of Results From Pivotal Phase 3 Clinical Trials With Locilex 10/20/2016
MicuRx Pharma Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA 10/20/2016
Daiichi Sankyo and Plexxikon Suspend Phase III Trial of Drug for Rare Tendon Cancer 10/19/2016
Merck & Co. (MRK)'s CMV Drug Passes Clinical Endpoints in Phase III Trial 10/19/2016
How Pfizer (PFE) is Quietly Rebuilding Its Alzheimer's Pipeline 10/19/2016
AbbVie (ABBV) Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At American Society for Reproductive Medicine Scientific Congress 10/19/2016
PAION AG: Positive Remimazolam Phase III Colonoscopy Results Presented At The 2016 American College of Gastroenterology Annual Scientific Meeting 10/19/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes? 10/18/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
PharmaMar Completes The Patient Recruitment For The "CORAIL" Phase III Pivotal Study With PM1183 10/18/2016
Ritter Pharmaceuticals, Inc. Concludes Last Patient Visit Of Its Phase 2b/3 Clinical Trial Of RP-G28 For The Treatment Of Lactose Intolerance 10/18/2016
Takeda (TKPYY) Showcases Continued Commitment In Hodgkin Lymphoma During 10th International Symposium On Hodgkin Lymphoma (ISHL) 10/18/2016
PharmaEngine, Inc. Announces Onivyde Receives European Marketing Authorization For The Treatment Of Metastatic Adenocarcinoma Of The Pancreas Following Gemcitabine Based Therapy 10/18/2016



//-->